Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04139343Completed

Motor Unit Number Estimation (MUNE) in Adults With Spinal Muscular Atrophy (SMA)

Role: collaborator

NCT03655223Enrolling By Invitation

Early Check: Expanded Screening in Newborns

Role: collaborator

NCT04591678Completed

Adults With SMA Treated With Nusinersen

Role: collaborator

NCT00466349Completed

International SMA Patient Registry

Role: collaborator

NCT01736553Completed

Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development

Role: collaborator

All 5 trials loaded